Wedbush analyst Robert Driscoll downgraded Alpine Immune Sciences (ALPN) to Neutral from Outperform with a price target of $65, up from $47, after the company agreed to an acquisition by Vertex Pharmaceuticals (VRTX) for $65 per share, or $4.9B in cash. The firm expects the acquisition to close.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALPN: